Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of C-Tactile-optimal Touch on Alcohol Craving and Relapse-Related Biomarkers in Alcohol Use Disorder

3 novembre 2026 aggiornato da: Aalto University

A Pilot Study to Assess the Effects of Mechanic Activation of C-tactile Afferent Nerves on Relapse Predicting Biomarkers and Alcohol Craving in AUD Patients During Early Abstinence, a 4-week Study

The aim of this trial is to investigate the effect of the activation of C-tactile afferents (CT) on relapse predicting biomarkers and subjective alcohol craving in alcohol use disorder (AUD) patients.

To test this in a laboratory environment, we will investigate the acute and chronic effect of mechanic CT activation vs. non-CT-activating control condition during exposure to validated craving-inducing visual stimuli in patients with AUD.We will assess several physiological measures that have been previously shown to indicate craving and predict relapse in patients with substance use disorder. These measures include pupillary reactivity, electroencephalography (EEG), salivary cortisol level and heart rate variability (HRV). These measures, together with the ratings of subjective craving, will be the primary endpoints of the investigation.

Primary objective is to test the hypothesis that CT activation may have therapeutic potential in treatment of AUD. Secondary objective is to investigate the safety and tolerability of mechanic optimal CT activation and its feasibility on modulation of certain biomarkers in AUD population.

40 early abstinent (≥ 2 weeks) female and male individuals of 18 to 60 years of age who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for mild to moderate AUD and who commonly engage in heavy alcohol consumption. However, the participants should precede two weeks of abstinence.

The study will include two experiments (Experiment 1. and Experiment 2.) that are conducted during two separate study visits with maximum seven days in between the visits.

Experiment 1. - Stress-related biomarkers in cue-, stress- and neutral stimuli exposure.

Experiment 1 aims to assess HPA-axis and autonomic nervoussystem reactivity before, during and after exposure to alcohol-, stress-, and neutral visual stimuli while either CT-optimal or non-CT-optimal robotic skin stimulation is provided. The primary biomarkers that will be monitored during the experiment are blood volume pulse (BVP), from which heart rate variability (HRV) will be derived from, and salivary cortisol level. In addition, self-reposted alcohol craving will be measuren with visual analog scale.

Five salivary cortisol samples will be collected at time points -20, -5, 0, +10 and +25. HRV will be derived from BVP and analysed with Kubios HRV Premium software.

All three visual stimuli conditions (neutral, alcohol and stress) will be given during the first study visit.

Experiment 2 - Cue-reactivity task test

In the cue-reactivity task pupillary reactivity, event related potentials (EVP's) of EEG will be measured during alcohol-related and neutral visual stimuli while the CT-optimal or non-CT-optimal skin stimulation is provided. Subjective craving will be self-reported by rating it on a 5-point VAS after each alcohol-related image.

The experiment will take place in an electrically shielded room provided by Aalto Behavioral Laboratory. The pupillary reactivity tracking and the EEG measuring systems will be connected to the PC providing the visual stimuli and the following tasks.

Two types of stimuli - 48 alcohol-related and 48 neutral images - will be presented so that each alcohol related image will be followed by a neutral image. The images will be centered on a white background and the colour, size and brightness of the alcohol and neutral stimuli will be matched. ). After each neutral image, the subject will be presented a question about the predominant colour in the image, which they will answer with the response pad. Once the subject has responded, the next stimulus image will be presented. The trial and the EEG and pupillometry recordings will finnish when the subject has responded to all images. In the end of the laboratory session, the subject will go through a relapse prevention session with an addiction medicine specialist to ensure that the distress caused by the experiments will not trigger a relapse outside of the laboratory.

Relapse prevention sessions

In both experiments the subjects will go through a relapse prevention session with an experienced addiction medicine specialist. The relapse prevention session will take place at the end of each laboratory session, after the exposure to the stimuli. The session consists of short motivational enhancement counselling designed to prevent relapsing.

Follow-up

The experiments will be followed by a two-week period during which the participant will report subjective craving, alcohol consumption and possible adverse events by filling an online diary (Appendix 6). If the participant does not have access to the internet, the diary may be filled manually.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

21

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Espoo, Finlandia
        • Aalto University, Department of Neuroscience and Biomedical Engineering and Aalto NeuroImaging (ANI) Infrastructure Aalto Behavioral Laboratory

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 60 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. The subject has blood alcohol cotent of 0.00% at the Visit 1.
  2. The subject has mild or moderate diagnosis of alcohol use disorder as measured by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
  3. Males and females aged 18 to 60.
  4. Able to provide Timeline Follow Back alcohol consumption information for the 28-day period prior to the Visit 1.
  5. A subject has had ≥6 heavy drinking days in the 4 weeks prior to the online screening.
  6. The subject has had ≤14 consecutive abstinent days preceding the Visit 1.
  7. Willingness to provide a saliva sample for cortisol analysis
  8. Able to read and understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of the relapse counselling.
  9. The subjects must have normal or corrected-to-normal eyesight.

Exclusion Criteria:

  1. Patients with withdrawal symptoms at the Visit 1, monitored with Clinical Institute Withdrawal Assessment of Alcohol Scale.
  2. Subjects with diagnosis of any of the following concomitant psychiatric disorders: non-treated, unstable schizophrenia, bipolar disorder, other psychotic disorder during the lifetime of the subject.

5. Subjects with current use of any other addictive substances (excluding nicotine).

6. The subject has been treated with any investigational medicinal product within 30 days.

7. The subject is currently participating or has recently (4 weeks prior to the Visit 1) participated in a treatment program for alcohol use disorders. 8. Dermatological conditions, especially on the targeted anatomical area. E.g., sun burns, cuts, eczema and fungal or other contagious skin diseases.

9. The subject has a clinically significant untreated and unstable illness, for example, hepatic or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance or chronic atrial fibrillation.

10. Current use of systemic steroids 11. Autism spectrum disorder (ASD). Score 26 or more in The Autism-Spectrum Quotient test.

13. The subject reports treatment, either current or within 28 days prior to the online screening, with any medications having a potential effect on alcohol consumption and related behaviours or mood. These include opiate antagonists (e.g., naltrexone, Vivitrol, Selincro), glutamate antagonists (e.g., acamprosate), anticonvulsants (e.g., topiramate), serotonin reuptake inhibitors (e.g., fluoxetine), serotonin antagonists (e.g., buspirone), other antidepressants (e.g., tricyclic antidepressants or monoamine oxidase inhibitors), dopamine antagonists (e.g., haloperidol), and disulfiram (Antabuse).

14. Current abuse of benzodiazepines. Benzodiazepines are allowed if used chronically.

15. Pregnancy by information given by the patient (non-invasive study). 16. Any other condition or therapy that in the investigator's opinion may pose a risk to the subject, prevent the subject from completing the required study procedures or interfere with the study objectives.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: CT-optimal touch

The active treatment is CT-optimal slow (3 cm/s) stroking tactile stimulation produced with a mechanically moving cosmetic brush

To eliminate the social aspect present in human touch, we use a robotic device to provide the CT-optimal dynamic touch. Both CT-optimal touch treatment and the non-CT-optimal control treatment are performed with the same custom made robotic device provides dynamic back-and forth strokes with a soft cosmetic brush on the skin of the non-dominant forearm of the participants. The CT-optimal treatment is performed at a velocity of 2.5-3 cm/s and a force of 200-300 mN. The non-CT-optimal control treatment is performed with velocity of 0.1-0.2 cm/s and a force similar to the CT-optimal treatment. The device is visible to the participants during the experiment.

Altri nomi:
  • Robotic CT-optimal touch
  • CT-optimal skin stimulation
  • CT-optimal stimulation
  • CT-optimal tactile stimulatin
Comparatore placebo: non-CT-optimal touch

The non-CT-optimal control treatment is performed with velocity of 0.1-0.2 cm/s and a force similar to the CT-optimal treatment with same robotic device as the Ct-optimal treatment.

To eliminate the social aspect present in human touch, we use a robotic device to provide the CT-optimal dynamic touch. Both CT-optimal touch treatment and the non-CT-optimal control treatment are performed with the same custom made robotic device provides dynamic back-and forth strokes with a soft cosmetic brush on the skin of the non-dominant forearm of the participants. The CT-optimal treatment is performed at a velocity of 2.5-3 cm/s and a force of 200-300 mN. The non-CT-optimal control treatment is performed with velocity of 0.1-0.2 cm/s and a force similar to the CT-optimal treatment. The device is visible to the participants during the experiment.

Altri nomi:
  • Non-CT-optimal touch

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Heart rate variability (HRV) reactivity as a biomarker of stress and a predictor of susceptibility to relapse
Lasso di tempo: Measurement taken during each participant's first study visit for approximately 32 minutes.

To assess autonomic functioning, Standard deviation of normal-to-normal intervals (SDNN) HRV (ms) is derived from blood volume pulse (BVP) measured with Empatica E4 wrist band device throughout Experiment 1. excluding a 15-minute relaxation at the end of the experimental session.

Measurement taken during each participant's first study visit for approximately 32 minutes.
Self-reported Alcohol craving
Lasso di tempo: The first and second study visits. Maximum 7 days in between the visits.

In the experiment performed during the first study visit a visual analog scale to assess self-reported subjective craving is shown before and after each cue exposure. The guestion "If alcohol was available to me right now..." is shown with a ten-point scale in which 1 = I would not want to drink it at all, 10 = I would not be able to resist drinking even if I tried. In the experiment at the second study visit a five-point visual analog scale for rating the alcohol craving is shown after each alcohol-related image in the cue reactivity task. In this on the queston is "How willing are you to drink the drink in the previous image…" 1 = I would not want to drink it at all, 5 = I would not be able to resist drinking even if I tried.

The first and second study visits. Maximum 7 days in between the visits.
Salivary cortisol as a biomarker of stress and a predictor of susceptibility to relapse
Lasso di tempo: First study visit. The time points of the saliva collection were the baseline, after the first 10 minutes of the treatment, after the visual stimuli, at the end of the treatment and after the 15-minute relaxation period.

To assess the salivary cortisol levels (ng/ml), saliva samples are collected 5 times during the Experiment 1. (total 15 samples per participant). The saliva is collected by placing a synthetic swab between the tongue and the cheek of the participants for minimum 2 min after which it was placed in a plastic tube and stored in -20 °C until the analysis.

First study visit. The time points of the saliva collection were the baseline, after the first 10 minutes of the treatment, after the visual stimuli, at the end of the treatment and after the 15-minute relaxation period.
Pupillary reactivity as a predictor of susceptibility to relapse
Lasso di tempo: Second study visit (maximum 7 seven days after ensrollment). Recorded during a cue reactivity task test for approximately 5 minutes.

Pupillary reactivity measurements are conducted in the Aalto Behavioral Laboratory (ABL) using an EyeLink 1000 Plus eye-tracking system during the Experiment 2. Pupil size (mm) is recorded continuously throughout the cue-reactivity task at a sampling frequency of 500 Hz. Pupil size is recorded monocularly from the participant's dominant eye, as determined prior to the session.

Second study visit (maximum 7 seven days after ensrollment). Recorded during a cue reactivity task test for approximately 5 minutes.
Event related potentials (ERP's) of electroencephalography (EEG) as a biomarker for predicting a vulnerability to relapses
Lasso di tempo: Second study visit (maximum 7 seven days after ensrollment. EEG will be recorded though out the cue reactivity task test for approximately 5 minute.

ERPs (microVolts) of EEG will be recorded using an BrainAmp amplifier and an ActiCap 32-channel electrode set during the cue reactivity task test (Experiment 2.) Focus will be on P3 amplitudes. Patients with AUD, as well as other substance use disorders, have larger P3 amplitudes elicited by substance-related than neutral stimuli which indicates that P3 amplitudes reflect the neural correlates of substance craving . In addition, the AUD patients with reduced P3 amplitudes to alcohol cues are less likely to relapse than those with larger P3 amplitudes.

Second study visit (maximum 7 seven days after ensrollment. EEG will be recorded though out the cue reactivity task test for approximately 5 minute.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of patients experiensing adverse reactions (Safety and Tolerability)
Lasso di tempo: 3 weeks from the enrollment (First and second study visits and a two-week follow-up)

Number of patients experiensing adverse reactions during the experimets and follow-up and numer of reported reactions

3 weeks from the enrollment (First and second study visits and a two-week follow-up)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Hannu Alho, Professor Emeritus, PhD, MD, University of Helsinki

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 gennaio 2023

Completamento primario (Effettivo)

29 settembre 2023

Completamento dello studio (Effettivo)

14 ottobre 2023

Date di iscrizione allo studio

Primo inviato

8 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 novembre 2026

Primo Inserito (Effettivo)

5 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • AY-NBE-HT-101

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

The data cannot be shared due to the GDPR regulations.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .